Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 22 studies | 61% ± 22% | |
lung | 19 studies | 43% ± 14% | |
intestine | 13 studies | 52% ± 23% | |
kidney | 9 studies | 36% ± 21% | |
liver | 7 studies | 46% ± 22% | |
brain | 6 studies | 34% ± 17% | |
bone marrow | 6 studies | 43% ± 28% | |
lymph node | 6 studies | 56% ± 28% | |
uterus | 5 studies | 58% ± 14% | |
adipose | 5 studies | 45% ± 22% | |
breast | 5 studies | 56% ± 20% | |
eye | 4 studies | 30% ± 17% | |
heart | 4 studies | 20% ± 2% | |
esophagus | 4 studies | 39% ± 20% | |
prostate | 4 studies | 45% ± 10% | |
adrenal gland | 3 studies | 49% ± 29% | |
pancreas | 3 studies | 23% ± 7% | |
stomach | 3 studies | 36% ± 24% | |
thymus | 3 studies | 61% ± 23% | |
skin | 3 studies | 50% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 17597.12 | 1444 / 1445 | 100% | 276.10 | 183 / 183 |
stomach | 100% | 13606.56 | 359 / 359 | 100% | 307.55 | 285 / 286 |
ovary | 100% | 33011.59 | 180 / 180 | 99% | 274.21 | 426 / 430 |
intestine | 100% | 24069.02 | 966 / 966 | 99% | 226.31 | 521 / 527 |
lung | 100% | 30288.49 | 576 / 578 | 93% | 115.11 | 1079 / 1155 |
breast | 100% | 34315.15 | 459 / 459 | 91% | 106.63 | 1018 / 1118 |
thymus | 100% | 36166.81 | 652 / 653 | 91% | 132.81 | 550 / 605 |
bladder | 100% | 17510.90 | 21 / 21 | 90% | 117.42 | 455 / 504 |
skin | 100% | 33641.23 | 1809 / 1809 | 87% | 66.37 | 410 / 472 |
prostate | 100% | 23903.69 | 245 / 245 | 85% | 94.42 | 427 / 502 |
pancreas | 91% | 7874.68 | 297 / 328 | 94% | 149.99 | 168 / 178 |
uterus | 100% | 20151.69 | 170 / 170 | 84% | 76.54 | 385 / 459 |
kidney | 99% | 10650.24 | 88 / 89 | 85% | 74.96 | 764 / 901 |
adrenal gland | 100% | 14798.70 | 258 / 258 | 43% | 22.00 | 100 / 230 |
liver | 77% | 6094.72 | 174 / 226 | 61% | 41.15 | 246 / 406 |
brain | 21% | 1357.23 | 557 / 2642 | 92% | 91.55 | 651 / 705 |
adipose | 100% | 33957.54 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 22295.08 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 27341.52 | 1332 / 1335 | 0% | 0 | 0 / 0 |
heart | 88% | 9136.21 | 757 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 80% | 68.93 | 36 / 45 |
peripheral blood | 67% | 6750.47 | 620 / 929 | 0% | 0 | 0 / 0 |
muscle | 66% | 6124.50 | 531 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 55% | 38.61 | 16 / 29 |
eye | 0% | 0 | 0 / 0 | 41% | 18.39 | 33 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045577 | Biological process | regulation of B cell differentiation |
GO_0071560 | Biological process | cellular response to transforming growth factor beta stimulus |
GO_0030097 | Biological process | hemopoiesis |
GO_0043488 | Biological process | regulation of mRNA stability |
GO_0006402 | Biological process | mRNA catabolic process |
GO_0048103 | Biological process | somatic stem cell division |
GO_0071364 | Biological process | cellular response to epidermal growth factor stimulus |
GO_0045599 | Biological process | negative regulation of fat cell differentiation |
GO_0061158 | Biological process | 3'-UTR-mediated mRNA destabilization |
GO_0097011 | Biological process | cellular response to granulocyte macrophage colony-stimulating factor stimulus |
GO_0033077 | Biological process | T cell differentiation in thymus |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0060216 | Biological process | definitive hemopoiesis |
GO_1900153 | Biological process | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay |
GO_0070371 | Biological process | ERK1 and ERK2 cascade |
GO_2000737 | Biological process | negative regulation of stem cell differentiation |
GO_1901991 | Biological process | negative regulation of mitotic cell cycle phase transition |
GO_0000288 | Biological process | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay |
GO_0071385 | Biological process | cellular response to glucocorticoid stimulus |
GO_0009611 | Biological process | response to wounding |
GO_0044344 | Biological process | cellular response to fibroblast growth factor stimulus |
GO_0035019 | Biological process | somatic stem cell population maintenance |
GO_0005737 | Cellular component | cytoplasm |
GO_1990904 | Cellular component | ribonucleoprotein complex |
GO_0005634 | Cellular component | nucleus |
GO_0035925 | Molecular function | mRNA 3'-UTR AU-rich region binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | ZFP36L2 |
Protein name | mRNA decay activator protein ZFP36L2 (Butyrate response factor 2) (EGF-response factor 2) (ERF-2) (TPA-induced sequence 11d) (Zinc finger protein 36, C3H1 type-like 2) (ZFP36-like 2) |
Synonyms | ERF2 TIS11D RNF162C |
Description | FUNCTION: Zinc-finger RNA-binding protein that destabilizes several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis . Acts as a 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signaling events to the mRNA decay machinery . Functions by recruiting the CCR4-NOT deadenylase complex and probably other components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs, and hence promotes ARE-mediated mRNA deadenylation and decay processes . Binds to 3'-UTR ARE of numerous mRNAs . Promotes ARE-containing mRNA decay of the low-density lipoprotein (LDL) receptor (LDLR) mRNA in response to phorbol 12-myristate 13-acetate (PMA) treatment in a p38 MAPK-dependent manner . Positively regulates early adipogenesis by promoting ARE-mediated mRNA decay of immediate early genes (IEGs). Plays a role in mature peripheral neuron integrity by promoting ARE-containing mRNA decay of the transcriptional repressor REST mRNA. Plays a role in ovulation and oocyte meiotic maturation by promoting ARE-mediated mRNA decay of the luteinizing hormone receptor LHCGR mRNA. Acts as a negative regulator of erythroid cell differentiation: promotes glucocorticoid-induced self-renewal of erythroid cells by binding mRNAs that are induced or highly expressed during terminal erythroid differentiation and promotes their degradation, preventing erythroid cell differentiation. In association with ZFP36L1 maintains quiescence on developing B lymphocytes by promoting ARE-mediated decay of several mRNAs encoding cell cycle regulators that help B cells progress through the cell cycle, and hence ensuring accurate variable-diversity-joining (VDJ) recombination process and functional immune cell formation. Together with ZFP36L1 is also necessary for thymocyte development and prevention of T-cell acute lymphoblastic leukemia (T-ALL) transformation by promoting ARE-mediated mRNA decay of the oncogenic transcription factor NOTCH1 mRNA. . |
Accessions | ENST00000282388.4 P47974 |